ONCAlert | Upfront Therapy for mRCC
Videos  >  

Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular Lymphoma

Carla Casulo, MD
Published Online:4:33 PM, Tue April 30, 2019

Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma (FL).

There is no clear way to distinguish which patients will do poorly after treatment, and there’s also no biomarkers to determine the response, says Casulo. With a plethora of options available, a physician might select therapy based on when the patient recurs; if a patient recurred early, those patients can be treated more aggressively, but an older patient might need to be considered for a more gentle approach.

For patients who have standard relapsed/refractory FL, there is no clear way to say which treatment may be more efficacious in a specific patient, Casulo concludes. This is due to a lack of predictors to response, which is a huge unmet need in this space.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.